Latest news with #PhareBio
Business Wire
2 days ago
- Business
- Business Wire
Phare Bio and MIT Named to Fast Company 's 2025 World Changing Ideas List
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Fast Company has named Phare Bio, a biotech social venture, and MIT's Collins Lab, to its 2025 World Changing Ideas list for their breakthrough use of generative AI to design entirely novel antibiotics – a paradigm-shifting approach in the global fight against antimicrobial resistance (AMR). Phare Bio and the Collins Lab's generative AI platform marks a significant leap forward in drug discovery, enabling researchers to design antibiotics in silico with unprecedented precision and speed. By layering multiple drug parameters into the design process – such as reducing toxicity or improving oral bioavailability – the platform can produce tailored antibiotic candidates with real-world clinical relevance. This year's recognition follows a major milestone in September 2024, when Phare Bio and the Collins Lab received an up to $27 million grant from ARPA-H to enhance this generative AI design capability and build a pipeline of 15 novel antibiotics tailored to meet global public health needs. 'We believe generative AI is not just accelerating drug discovery – it's redefining what's possible,' said Dr. Akhila Kosaraju, CEO and President of Phare Bio. 'To be named to Fast Company's World Changing Ideas list is an incredible honor, and a reflection of what happens when breakthrough science, technology and a commitment to real-world impact converge.' Building off of the Collins Lab's first-ever discovery of a novel antibiotic using AI, Phare Bio's goal is simple and urgent: to design smarter antibiotics for the patients who need them most. 'This recognition is deeply meaningful for Phare Bio and our lab at MIT,' said Dr. Jim Collins, Co-founder of Phare Bio, Termeer Professor of Medical Engineering & Science and Professor of Biological Engineering at MIT. 'Over the past decade, our team has worked at the forefront of artificial intelligence and synthetic biology to chart a new era in antibiotic discovery. We're excited to see this work scale into a global movement to reinvigorate antibiotic innovation.' 'The World Changing Ideas Awards have always been about showcasing the art of the possible,' says Brendan Vaughan, editor-in-chief at Fast Company. 'We're proud to recognize the organizations and leaders that are making meaningful progress on the biggest issues of our time.' By combining deep learning, data-driven design, and open-access collaboration, Phare Bio and the Collins Lab are creating a new gold standard for how antibiotics are discovered and developed. About Phare Bio Phare Bio is a social venture using artificial intelligence (AI) to develop novel classes of antibiotics in partnership with Jim Collins' lab at MIT. Founded in 2020 to address the growing crisis of antibiotic resistance, Phare Bio is a recipient of the Audacious Project, a collaborative funding initiative between TED and leading nonprofits to support bold solutions to global challenges. The company combines cutting-edge machine learning with world-class science to accelerate the discovery of urgently needed antibiotics. To learn more, visit or email info@
Business Wire
3 days ago
- Health
- Business Wire
Phare Bio Selected to Participate in the
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Phare Bio, a biotech social venture using AI to combat the global antibiotic resistance crisis, has been selected to participate in the Accelerator: Generative AI – to advance its groundbreaking work in antibiotic research and development. Along with a share of $30 million in funding, Phare Bio will receive 6 months of pro bono technical expertise to support the continued buildout of Phare Bio's AI-powered, open-access drug discovery platform – a resource designed to galvanize global researchers and reinvigorate antibiotic innovation at a time of mounting public health urgency. Phare Bio's platform, built in partnership with the Collins Lab at MIT, harnesses the power of generative AI to design entirely new classes of antibiotics. The platform integrates advanced machine learning models with biological screening to rapidly identify and optimize drug candidates with high precision and reduced toxicity. This work aims to address antibiotic resistance, a silent pandemic expected to claim nearly 40 million lives worldwide by 2050. 'This support from helps ensure that the tools we're building don't just stay in the lab – they empower researchers, developers, and communities around the world to accelerate their own antibiotic discoveries,' said Dr. Akhila Kosaraju, CEO and President of Phare Bio. 'This investment in open-access infrastructure reflects a shared commitment to science as a global public good.' This support builds off the extraordinary momentum and support from ARPA-H and the Audacious Project, underscoring Phare Bio's growing impact and potential. These resources are helping expand the platform's generative AI capabilities, enabling researchers to virtually design customized antibiotic candidates with properties tailored to real-world clinical needs – a radical shift in drug discovery. Karla Palmer, Manager, AI & Scientific Progress, at added: 'We were inspired by Phare Bio's vision to not only reinvent antibiotic discovery through AI but to make those tools available to the broader scientific community. Their platform has the potential to catalyze a new era of global collaboration and accelerate progress against one of the world's most urgent health threats.' With a goal to develop 15 preclinical antibiotics by 2030, Phare Bio is setting a new gold standard for mission-aligned biotech innovation. About Phare Bio Phare Bio is a social venture using artificial intelligence (AI) to develop novel classes of antibiotics in partnership with Jim Collins' lab at MIT. Founded in 2020 to address the growing crisis of antibiotic resistance, Phare Bio is a recipient of the Audacious Project, a collaborative funding initiative between TED and leading nonprofits to support bold solutions to global challenges. The company combines cutting-edge machine learning with world-class science to accelerate the discovery of urgently needed antibiotics. To learn more, visit or email info@
